Myricitrin Alleviates Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease in High Cholesterol Diet-Fed Mice
Nutrients · 2025
DOI: 10.3390/nu17030415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Young-Je Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food Science and Nutrition, Kyungpook National University, Daegu 41566, Republic of Korea. Hauptthemen laut MEDLINE: Hypercholesterolemia, Non-alcoholic Fatty Liver Disease, Flavonoids, Diet. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: a Research Grant of Pukyong National University, Pukyong National University.
Abstract (Originalsprache)
Background/Objectives: This research investigated the effects of myricitrin on hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD) in mice given a high-cholesterol diet (HCD).
Methods
C57BL/6J mice were maintained for 20 weeks on an HCD with or without myricitrin.
Results
Myricitrin had no impact on the food consumption, body weight, or plasma triglyceride concentrations. However, myricitrin-supplemented mice had lower plasma total cholesterol (TC) concentrations and LDL + VLDL-cholesterol/TC proportion, and higher HDL-cholesterol/TC proportion than control mice, which resulted in a markedly decreased atherogenic index. Moreover, the levels of plasma C-reactive protein, oxidized LDL, lipoprotein(a), and plasminogen activator inhibitor-1, which are indicators for cardiovascular disease (CVD), were reduced, while levels of plasma paraoxonase, a cardioprotective enzyme, were greater in myricitrin-supplemented mice than in control mice. Myricitrin also meaningfully reduced liver weight and hepatic cholesterol content, and slightly alleviated fatty liver and fibrosis caused by an HCD. The plasma and hepatic cholesterol-lowering effects of myricitrin were partly associated with decreased activities of hepatic 3-hydroxy-3-methylglutaryl-CoA reductase and acyl-CoA:cholesterol acyltransferase, which are involved in cholesterol synthesis and esterification, respectively, as well as mRNA expression. Myricitrin also altered other hepatic genes implicated in cholesterol homeostasis, including the downregulation of SREBP2 and ABCA1 mRNA expression and the upregulation of LDLR mRNA expression. Moreover, myricitrin decreased TBARS levels in the liver and erythrocytes by activating antioxidant enzymes (SOD and catalase).
Conclusions
These results indicate that dietary myricitrin may offer therapeutic benefits for HCD-caused hypercholesterolemia and NAFLD, and may help reduce CVD risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Food Science and Nutrition, Kyungpook National University, Daegu 41566, Republic of Korea.
- Department of Food Science and Nutrition, Pukyong National University, 45 Yongso-ro, Nam-gu, Busan 48513, Republic of Korea.
- School of Life Sciences, Kyungpook National University, Daegu 41566, Republic of Korea.
ORCID-Profile: Sang Ryong Kim, Un Ju Jung
Förderung
- a Research Grant of Pukyong National University
- Pukyong National University
Zitieren
APA
Kim, Y. J., Park, S., Kim, H., Kim, S. R., & Jung, U. J. (2025). Myricitrin Alleviates Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease in High Cholesterol Diet-Fed Mice. Nutrients. https://doi.org/10.3390/nu17030415
Vancouver
Kim YJ, Park S, Kim H, Kim SR, Jung UJ. Myricitrin Alleviates Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease in High Cholesterol Diet-Fed Mice. Nutrients. 2025. doi:10.3390/nu17030415
BibTeX
@article{Kim2025,
author = {Kim, Young-Je and Park, Sojeong and Kim, HwiCheol and Kim, Sang Ryong and Jung, Un Ju},
title = {Myricitrin Alleviates Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease in High Cholesterol Diet-Fed Mice},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu17030415}
}
EUVIMED